- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BAYZF
Recent news which mentions BAYZF
Top Catalysts For DAX Index And Best Stocks Of 2025 Revealed
August 17, 2025
From TalkMarkets
Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
July 25, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
March 19, 2024
From Benzinga
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
March 14, 2024
From Benzinga
Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
March 05, 2024
From Benzinga
What's Going On With BridgeBio Pharma Stock On Monday?
March 04, 2024
From Benzinga
From Benzinga
From Benzinga
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
From Benzinga
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
January 08, 2024
From Benzinga
From Benzinga
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
December 26, 2023
From Benzinga
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
December 19, 2023
From Benzinga
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
December 06, 2023
From Benzinga
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
December 04, 2023
From Benzinga
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
November 24, 2023
From Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
November 20, 2023
From Benzinga
From Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
November 17, 2023
From Benzinga
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
November 08, 2023
From Benzinga
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
November 01, 2023
From Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
From Benzinga
From Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
August 28, 2023
From Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
August 21, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.